Differentiated Thyroid Cancer Incidentally Detected by ¹⁸F-FDG PET/CT: Patient's Future in a Hot-spot?

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2014 May 15

PMID 24824461

Citations 2

Authors

Silvia Morbelli

Marcello Bagnasco

Affiliations

Soon will be listed here.

Citing Articles

Relationship between circulating anti-thyroglobulin antibodies (TgAb) and tumor metabolism in patients with differentiated thyroid cancer (DTC): prognostic implications.

Morbelli S, Ferrarazzo G, Pomposelli E, Pupo F, Pesce G, Calamia I J Endocrinol Invest. 2016; 40(4):417-424.

PMID: 27844413 DOI: 10.1007/s40618-016-0578-6.

Employing Bayesian approach to the intermediate risk categories of the Bethesda thyroid cytopathology reporting system: can FDG PET/CT find a strong enough evidence-base to be practised clinically as an adjunct?.

Basu S Eur J Nucl Med Mol Imaging. 2014; 41(12):2354-5.

PMID: 25201009 DOI: 10.1007/s00259-014-2908-2.

References

Treglia G, Bertagna F, Sadeghi R, Verburg F, Ceriani L, Giovanella L . Focal thyroid incidental uptake detected by ¹⁸F-fluorodeoxyglucose positron emission tomography. Meta-analysis on prevalence and malignancy risk. Nuklearmedizin. 2013; 52(4):130-6. DOI: 10.3413/Nukmed-0568-13-03. View

Robbins R, Wan Q, Grewal R, Reibke R, Gonen M, Strauss H . Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab. 2005; 91(2):498-505. DOI: 10.1210/jc.2005-1534. View

Are C, Hsu J, Ghossein R, Schoder H, Shah J, Shaha A . Histological aggressiveness of fluorodeoxyglucose positron-emission tomogram (FDG-PET)-detected incidental thyroid carcinomas. Ann Surg Oncol. 2007; 14(11):3210-5. DOI: 10.1245/s10434-007-9531-4. View

Welch H, Black W . Overdiagnosis in cancer. J Natl Cancer Inst. 2010; 102(9):605-13. DOI: 10.1093/jnci/djq099. View

Piccardo A, Puntoni M, Bertagna F, Treglia G, Foppiani L, Arecco F . ¹⁸F-FDG uptake as a prognostic variable in primary differentiated thyroid cancer incidentally detected by PET/CT: a multicentre study. Eur J Nucl Med Mol Imaging. 2014; 41(8):1482-91. DOI: 10.1007/s00259-014-2774-y. View

Law T, Lang B . Incidental thyroid carcinoma by FDG-PET/CT: a study of clinicopathological characteristics. Ann Surg Oncol. 2010; 18(2):472-8. PMC: 3032177. DOI: 10.1245/s10434-010-1287-6. View

Silver R, Parangi S . Management of thyroid incidentalomas. Surg Clin North Am. 2004; 84(3):907-19. DOI: 10.1016/j.suc.2004.02.002. View

Morris L, Sikora A, Tosteson T, Davies L . The increasing incidence of thyroid cancer: the influence of access to care. Thyroid. 2013; 23(7):885-91. PMC: 3704124. DOI: 10.1089/thy.2013.0045. View

Pacini F, Schlumberger M, Dralle H, Elisei R, Smit J, Wiersinga W . European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006; 154(6):787-803. DOI: 10.1530/eje.1.02158. View

10.

Cooper D, Doherty G, Haugen B, Hauger B, Kloos R, Lee S . Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009; 19(11):1167-214. DOI: 10.1089/thy.2009.0110. View

11.

Tuttle R, Leboeuf R . Follow up approaches in thyroid cancer: a risk adapted paradigm. Endocrinol Metab Clin North Am. 2008; 37(2):419-35, ix-x. DOI: 10.1016/j.ecl.2008.02.008. View

12.

Piccardo A, Foppiani L, Morbelli S, Bianchi P, Barbera F, Biscaldi E . Could [18]F-fluorodeoxyglucose PET/CT change the therapeutic management of stage IV thyroid cancer with positive (131)I whole body scan?. Q J Nucl Med Mol Imaging. 2011; 55(1):57-65. View

13.

Furtado C, Aguirre D, Sirlin C, Dang D, Stamato S, Lee P . Whole-body CT screening: spectrum of findings and recommendations in 1192 patients. Radiology. 2005; 237(2):385-94. DOI: 10.1148/radiol.2372041741. View

14.

Pak K, Kim S, Kim I, Kim B, Kim S, Jeon Y . The role of 18F-fluorodeoxyglucose positron emission tomography in differentiated thyroid cancer before surgery. Endocr Relat Cancer. 2013; 20(4):R203-13. DOI: 10.1530/ERC-13-0088. View

15.

Tuttle R . Risk-adapted management of thyroid cancer. Endocr Pract. 2008; 14(6):764-74. DOI: 10.4158/EP.14.6.764. View

16.

Castagna M, Maino F, Cipri C, Belardini V, Theodoropoulou A, Cevenini G . Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. Eur J Endocrinol. 2011; 165(3):441-6. DOI: 10.1530/EJE-11-0466. View